Biohaven Ltd. (NYSE:BHVN) agreed to acquire Pyramid Biosciences, Inc. for $50 million on January 7, 2024. In consideration for the Pyramid acquisition, an upfront payment of $10.0 million of our common shares. Biohaven Ltd. also agreed to make additional success-based payments up to $40.0 million upon achievement of certain regulatory milestones, which Biohaven Ltd. may elect to pay in cash or our common shares. In January 2024, a $5.0 million payment became due to Pyramid related to achievement of a regulatory milestone under the Pyramid Agreement, which we elected to pay in our common shares. The shares related to both of these payments were not registered under the Securities Act.

Biohaven Ltd. (NYSE:BHVN) completed the acquisition of Pyramid Biosciences, Inc. in January, 2024.